Skip to content

Effects of Enhanced External Counterpulsation Therapy on Brain function, Cognitive function, and Upper Limb Motor Function in Subacute Cerebral Infarction: A Randomized, Controlled Trial

Effects of Enhanced External Counterpulsation Therapy on Brain function, Cognitive function, and Upper Limb Motor Function in Subacute Cerebral Infarction: A Randomized, Controlled Trial

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078267
Enrollment
Unknown
Registered
2023-12-01
Start date
2024-01-01
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subacute cerebral Infarction

Interventions

real treatment group:150mmHg-EECP
sham treatment group:75mmHg-EECP

Sponsors

The First Affiliated Hospital,Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1)Patients eligible for this study are aged 18 years or older and no more than 80 years old; (2)Patients have experienced their first stroke within 1 to 3 weeks 28 without prior rehabilitation; (3)Patients possess a confirmed diagnosis of a first-ever unilateral MCA-territory IS via head CT and MRI; (4)Patients exhibit an initial upper-limb function of Brunnstrom stage II-IV; (5)Patients demonstrate general cognitive abilities (MMSE > 21); (6)Patients provide voluntary informed consent.

Exclusion criteria

Exclusion criteria: (1)Patients meeting any of the following criteria will be excluded: evidence of cardioembolic stroke, brain hemorrhage on CT, arteriovenous malformation, arteriovenous fistula, or aneurysm; (2)A history of intracerebral hemorrhage, brain tumor, or malignancy; (3)Sustained hypertension (SBP > 180mmHg or DBP > 100mmHg); (4)Severe symptomatic peripheral vascular disease; (5)Coexisting systemic diseases such as renal failure (creatinine > 300µmol/L), cirrhosis, or thrombocytopenia (platelet count < 100,000/mm3); (6)Severe dementia or psychosis; (7)Pregnancy.

Design outcomes

Primary

MeasureTime frame
fNIRS;

Secondary

MeasureTime frame
fugl-Meyer;MMSE;ACE-III;Berg;The Barthel index of ADL;

Countries

China

Contacts

Public ContactZhang Yushu

The First Affiliated Hospital,Sun Yat-sen University

zhangysh66@mail.sysu.edu.cn+86 189 4010 0821

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026